NASDAQ · Health care

20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs, Inc. reported revenue of $2M in fiscal 2025, up 16.7% from a year earlier. It posted a net loss of $3.7M. At June 30, 2026 it held $4.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$0.43

+2.74% on the day · September 25, 2026

52-week range $0.40 to $50.00

Market cap

$5.6M

Revenue (FY2025)

$2M

+16.7% year on year

Net margin

-182.8%

What 20/20 Biolabs, Inc. does

20/20 Biolabs, Inc. is registered with the SEC under industry code SIC 8734 (Services-Testing Laboratories). Its shares trade on NASDAQ under the ticker AIDX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$2M	-$3.3M	-$3.7M	-$0.76	n/a
2025	$1.8M	-$5.7M	-$5.6M	-$1.16	n/a

Next report expected around October 26, 2026.

Estimated from its filing rhythm: about 69 days after its last report of August 17, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where AIDX ranks in Health care

Revenue$2M

#542 of 646 in Health care · Bottom 16%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What 20/20 Biolabs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 18, 2026
Shareholder vote results 8-K
September 10, 2026
Stock exchange listing notice 8-K
September 2, 2026
Investor disclosure 8-K
August 19, 2026
Additional proxy material DEFA14A
August 19, 2026
Shareholder vote results 8-K
August 17, 2026
Securities offering prospectus 424B3
August 17, 2026
Securities offering prospectus 424B3
August 17, 2026
Quarterly results 8-K
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 37% to $730.6K versus the same quarter last year; diluted EPS -$0.26 versus -$0.17.
August 5, 2026
Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 6, 2026. Insider transactions on SEC

Who owns AIDX

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Jonathan M Cohen13D, may seek influence	16.8%	1,833,750	March 10, 2026
Streeterville Capital LLC13G, passive with 2 related filers	9.9%	543,680	February 25, 2026
Full Succeed International Limited13G, passive with 2 related filers	6.3%	651,465	March 10, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about AIDX

What does 20/20 Biolabs, Inc. do?

20/20 Biolabs, Inc. is registered with the SEC under industry code SIC 8734 (Services-Testing Laboratories). Its shares trade on NASDAQ under the ticker AIDX.

Is 20/20 Biolabs, Inc. profitable?

No. In fiscal 2025 it reported a net loss of $3.7M on revenue of $2M.

How much revenue does 20/20 Biolabs, Inc. make?

In fiscal 2025 20/20 Biolabs, Inc. reported revenue of $2M. That is 16.7% more than a year earlier.

When did 20/20 Biolabs, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 18, 2026.

Similar companies

Unitedhealth Group Inc

Compare AIDX with

Compare AIDX with any company

Follow AIDX

Get an email when 20/20 Biolabs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow AIDX: get an email when it files

Where the numbers come from

Financial figures are the values 20/20 Biolabs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.